Foresite Capital Management IV, LLC Diversified Active

Name: Foresite Capital Management IV, LLC Q4 2022 13F Filing | 13F Explorer
Creator: Foresite Capital Management IV, LLC
Published: 2023-02-13

Location: West Hollywood, CA

CIK: 0001704132 · Show all filings

Period: Q4 2022 (← Previous) (Next →)

Filing Date: Feb 13, 2023

Total Value: $234M (100.0% shares, 0.0% debt)

Holdings (8)

— Kinnate Biopharma Inc. 25.2%

Value $59M Shares 9,671,643 Est. Cost $39.78 Unrealized —

ACRS Aclaris Therapeutics, Inc. 18.9%

Value $44.23M Shares 2,808,034 Est. Cost $15.18 Unrealized +6.0%

PHVS Pharvaris N.V. 15.6%

Value $36.53M Shares 3,246,926 Est. Cost $31.46 Unrealized -83.3%

— Lyell Immunopharma, Inc. 14.8%

Value $34.7M Shares 10,000,000 Est. Cost $16.24 Unrealized —

KURA Kura Oncology, Inc. 9.8%

Value $22.96M Shares 1,849,947 Est. Cost $20.39 Unrealized -28.7%

SNDX Syndax Pharmaceuticals, Inc. 9.5%

Value $22.27M Shares 875,000 Est. Cost $22.62 Unrealized +3.1%

— Cymabay Therapeutics, Inc. 4.8%

Value $11.21M Shares 1,787,094 Est. Cost $3.49 Unrealized —

QSI Quantum-Si Incorporated 1.4%

Value $3.241M Shares 1,771,249 Est. Cost $10.48 Unrealized -75.4%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Kinnate Biopharma Inc.	9,671,643	$59M	25.2%	$39.78	—	COM	49705R105
ACRS	Aclaris Therapeutics, Inc.	2,808,034	$44.23M	18.9%	$15.18	+6.0%	COM	00461U105
PHVS	Pharvaris N.V.	3,246,926	$36.53M	15.6%	$31.46	-83.3%	COM	N69605108
—	Lyell Immunopharma, Inc.	10,000,000	$34.7M	14.8%	$16.24	—	COM	55083R104
KURA	Kura Oncology, Inc.	1,849,947	$22.96M	9.8%	$20.39	-28.7%	COM	50127T109
SNDX	Syndax Pharmaceuticals, Inc.	875,000	$22.27M	9.5%	$22.62	+3.1%	COM	87164F105
—	Cymabay Therapeutics, Inc.	1,787,094	$11.21M	4.8%	$3.49	—	COM	23257D103
QSI	Quantum-Si Incorporated	1,771,249	$3.241M	1.4%	$10.48	-75.4%	COM CL A	74765K105